Michael Barbella, Managing Editor04.26.23
Route 92 Medical Inc. has been issued its 80th global patent for its Monopoint Operating Platform, which streamlines delivery of large and super-bore catheters for aspiration at the most common stroke targets. The single-platform system aims to improve the efficiency and efficacy of neurovascular intervention with a design that eliminates length challenges and provides a single point of control for enhanced single-operator capability.
“Route 92 Medical is poised to disrupt the neuro-interventional market with products that are designed to treat ischemic strokes by enhancing delivery in challenging anatomy using our unique single-point-of-control approach,” Route 92 Medical Founder/CEO Tony Chou, M.D., said. “Our intellectual property strength, combined with our team, give us a strong position from which we can make a positive difference in the lives of stroke patients and their families.”
U.S. Patent No. 11,576,691 relates to the company’s Tenzing delivery catheter for advancing catheter systems within the neurovasculature. The Tenzing catheter is part of the Monopoint platform, which enables a single operator to perform even the most complex procedures to treat large vessel occlusions that cause acute ischemic stroke.
“The past 20 years have seen extensive research on patient selection for stroke intervention with limited device innovation,” Route 92 Medical Chief Technology Officer John Miller stated. “We are focused on simplifying neurovascular procedures so physicians can reduce procedure times and improve clinical outcomes.”
Route 92 Medical has a global intellectual property position with strong protection for its inventions in key markets including the United States, Europe, and China. The company patent portfolio is growing rapidly with 46 patents issued in 2022 including patents with claims across the company’s Monopoint portfolio, including its Tenzing and HiPoint catheter devices.
Founded by physicians, Route 92 Medical collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions.
“Route 92 Medical is poised to disrupt the neuro-interventional market with products that are designed to treat ischemic strokes by enhancing delivery in challenging anatomy using our unique single-point-of-control approach,” Route 92 Medical Founder/CEO Tony Chou, M.D., said. “Our intellectual property strength, combined with our team, give us a strong position from which we can make a positive difference in the lives of stroke patients and their families.”
U.S. Patent No. 11,576,691 relates to the company’s Tenzing delivery catheter for advancing catheter systems within the neurovasculature. The Tenzing catheter is part of the Monopoint platform, which enables a single operator to perform even the most complex procedures to treat large vessel occlusions that cause acute ischemic stroke.
“The past 20 years have seen extensive research on patient selection for stroke intervention with limited device innovation,” Route 92 Medical Chief Technology Officer John Miller stated. “We are focused on simplifying neurovascular procedures so physicians can reduce procedure times and improve clinical outcomes.”
Route 92 Medical has a global intellectual property position with strong protection for its inventions in key markets including the United States, Europe, and China. The company patent portfolio is growing rapidly with 46 patents issued in 2022 including patents with claims across the company’s Monopoint portfolio, including its Tenzing and HiPoint catheter devices.
Founded by physicians, Route 92 Medical collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions.